用大鸡巴操美女视频,亚洲国产成人艾草网之颜值,91九色在线精品人妻

OVERVIEW

Incorporated in Shanghai International Medical Zone in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec?”) is one of the first companies listed on the SSE STAR Market (stock code: 688016.SH) in 2019. It has been granted the titles of National Enterprise Technology Center, National Technological Innovation Demonstration Enterprise, one of the first Chinese Specialized and Sophisticated “Little Giant” Enterprises that Produce Novel and Unique Products, national-level “Green Factory”, National High-tech Enterprise, Multinational R&D Center, Shanghai Municipal Sci-tech “Little Giant” Enterprise, Shanghai Municipal Enterprise Technology Center, and AAA Credit-Rating Enterprise, as well as honors such as China Patent Gold Award, the National Intellectual Property Advantage Enterprise, Shanghai Municipal Quality Gold Award, Shanghai Municipal Quality Benchmark, and Shanghai Brand.

Endovastec? focuses on the research and development (R&D), manufacturing, sales and services of aortic, peripheral vascular and tumor intervention devices. Endovastec?’s subsidiaries include Bluevastec?, VasoLutions?, Intervastec?, Endovastec US?, and Lombard Medical, among others, which are committed to the R&D and sales of intervention medical devices for peripheral venous diseases, peripheral arterial diseases, and tumor diseases, respectively. The company currently has 31 products on the market worldwide, of which 5 have obtained CE marking, mainly including thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters and snare retrieval kits. As of June 2025, the products of Endovastec? have been available in over 2,700 hospitals across China and reached over 40 countries and regions worldwide, saving or improving more than 350,000 lives globally. In 2021, the domestic market share of our aortic endovascular intervention products has reached 29%, ranking first in China. At present, the company’s domestic operations cover 31 provinces, autonomous regions, municipalities, and the Hong Kong and Macao special administrative regions in China, while its international operations extend to Europe, Latin America, Asia, Africa and many other regions.

With technological innovation as its core driving force and upholding the innovation philosophy of “being the number one or the only one”, Endovastec? is striving for development through rapid innovation. In recent years, the company’s annual investment in research and development has accounted for approximately 15% of its annual revenue. The R&D personnel comprise over 25% of the total company workforce, including a group of top-notch scientific research professionals. As of June 2025, the company has obtained more than 250 patents authorized domestically and internationally, including 170 invention patents. It has won the second prize of the Chinese National Science and Technology Progress Award, and has won the first prize of the Shanghai Municipal Science and Technology Progress Award twice. At present, among the products already launched and under development, nine have been approved by the National Medical Products Administration (NMPA) of China to go through the Special Review Procedures for Innovative Medical Devices (Green Path), outperforming most other companies in the industry. A collection of clinical academic articles on its key products has been published in internationally renowned medical journals.

The operation headquarters of Endovastec? is located in Shanghai, with nearly 24,000 square meters of R&D, manufacturing and office space, more than 5,000 square meters of Class 10,000 clean rooms in line with the national standards for the production of Class III implantable products. Advocating that “the patient always comes first” and adhering to the mission of providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, Endovastec? is committed to building a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.